Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized, double-blind, placebo-controlled study of spesolimab in moderate or severe hidradenitis suppurativa
2020-003672-40Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Spesolimab with Placebo (2 arms). Primary endpoint: Percent change from baseline in total abscess and inflammatory nodule count at Week 12. Started Dec 2020; status: completed.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2020-003672-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003672-40.